Annual Working Capital
$24.40 M
+$11.95 M+95.98%
December 31, 2023
Summary
- As of February 8, 2025, PLX annual working capital is $24.40 million, with the most recent change of +$11.95 million (+95.98%) on December 31, 2023.
- During the last 3 years, PLX annual working capital has risen by +$55.15 million (+179.35%).
- PLX annual working capital is now -67.31% below its all-time high of $74.65 million, reached on December 31, 2015.
Performance
PLX Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Working Capital
$23.63 M
+$4.24 M+21.85%
September 30, 2024
Summary
- As of February 8, 2025, PLX quarterly working capital is $23.63 million, with the most recent change of +$4.24 million (+21.85%) on September 30, 2024.
- Over the past year, PLX quarterly working capital has dropped by -$5.63 million (-19.23%).
- PLX quarterly working capital is now -70.45% below its all-time high of $79.97 million, reached on September 30, 2013.
Performance
PLX Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Working Capital Formula
Working Capital = Current Assets − Current Liabilities
PLX Working Capital Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +96.0% | -19.2% |
3 y3 years | +179.3% | -19.2% |
5 y5 years | -11.7% | -19.2% |
PLX Working Capital Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -14.3% | +96.0% | -53.2% | +106.3% |
5 y | 5-year | -14.3% | +179.3% | -53.2% | +176.8% |
alltime | all time | -67.3% | +179.3% | -70.5% | +176.8% |
Protalix BioTherapeutics Working Capital History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $23.63 M(+21.9%) |
Jun 2024 | - | $19.39 M(-5.7%) |
Mar 2024 | - | $20.58 M(-15.7%) |
Dec 2023 | $24.40 M(+96.0%) | $24.40 M(-16.6%) |
Sep 2023 | - | $29.26 M(-42.0%) |
Jun 2023 | - | $50.47 M(+111.3%) |
Mar 2023 | - | $23.89 M(+91.8%) |
Dec 2022 | $12.45 M(-56.3%) | $12.45 M(+8.7%) |
Sep 2022 | - | $11.46 M(-38.9%) |
Jun 2022 | - | $18.74 M(-11.6%) |
Mar 2022 | - | $21.21 M(-25.5%) |
Dec 2021 | $28.49 M(-192.6%) | $28.49 M(+0.1%) |
Sep 2021 | - | $28.46 M(-8884.0%) |
Jun 2021 | - | -$324.00 K(-103.3%) |
Mar 2021 | - | $9.84 M(-132.0%) |
Dec 2020 | -$30.75 M(+299.6%) | -$30.75 M(-287.1%) |
Sep 2020 | - | $16.44 M(+39.4%) |
Jun 2020 | - | $11.79 M(+16.3%) |
Mar 2020 | - | $10.14 M(-231.7%) |
Dec 2019 | -$7.70 M(-127.9%) | -$7.70 M(-208.1%) |
Sep 2019 | - | $7.12 M(-54.4%) |
Jun 2019 | - | $15.61 M(-23.1%) |
Mar 2019 | - | $20.30 M(-26.5%) |
Dec 2018 | $27.63 M(-30.8%) | $27.63 M(-35.4%) |
Sep 2018 | - | $42.79 M(+52.9%) |
Jun 2018 | - | $27.98 M(-18.2%) |
Mar 2018 | - | $34.19 M(-14.3%) |
Dec 2017 | $39.90 M(+605.6%) | $39.90 M(+62.4%) |
Sep 2017 | - | $24.56 M(-17.5%) |
Jun 2017 | - | $29.77 M(-27.8%) |
Mar 2017 | - | $41.25 M(+629.5%) |
Dec 2016 | $5.66 M(-92.4%) | $5.66 M(-88.5%) |
Sep 2016 | - | $49.31 M(-12.2%) |
Jun 2016 | - | $56.19 M(-16.1%) |
Mar 2016 | - | $66.99 M(-10.3%) |
Dec 2015 | $74.65 M(+6301.9%) | $74.65 M(+198.3%) |
Sep 2015 | - | $25.02 M(-11.7%) |
Jun 2015 | - | $28.35 M(-14.2%) |
Mar 2015 | - | $33.03 M(+2733.2%) |
Dec 2014 | $1.17 M(-98.4%) | $1.17 M(-97.5%) |
Sep 2014 | - | $46.82 M(-15.2%) |
Jun 2014 | - | $55.19 M(-10.7%) |
Mar 2014 | - | $61.78 M(-13.2%) |
Dec 2013 | $71.21 M(+101.1%) | $71.21 M(-11.0%) |
Sep 2013 | - | $79.97 M(+314.3%) |
Jun 2013 | - | $19.30 M(-32.2%) |
Mar 2013 | - | $28.49 M(-19.6%) |
Dec 2012 | $35.41 M(+156.7%) | $35.41 M(-9.5%) |
Sep 2012 | - | $39.15 M(-12.1%) |
Jun 2012 | - | $44.56 M(+38.8%) |
Mar 2012 | - | $32.11 M(+132.7%) |
Dec 2011 | $13.80 M | $13.80 M(-37.2%) |
Sep 2011 | - | $21.97 M(-28.9%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2011 | - | $30.91 M(-26.6%) |
Mar 2011 | - | $42.12 M(+53.6%) |
Dec 2010 | $27.43 M(-55.7%) | $27.43 M(-27.7%) |
Sep 2010 | - | $37.95 M(-11.7%) |
Jun 2010 | - | $42.98 M(-19.2%) |
Mar 2010 | - | $53.17 M(-14.1%) |
Dec 2009 | $61.88 M(+63.4%) | $61.88 M(+236.4%) |
Sep 2009 | - | $18.39 M(-26.0%) |
Jun 2009 | - | $24.86 M(-21.3%) |
Mar 2009 | - | $31.61 M(-16.5%) |
Dec 2008 | $37.86 M(-36.3%) | $37.86 M(-15.0%) |
Sep 2008 | - | $44.56 M(-12.5%) |
Jun 2008 | - | $50.94 M(-8.5%) |
Mar 2008 | - | $55.67 M(-6.3%) |
Dec 2007 | $59.41 M(+169.7%) | $59.41 M(+213.8%) |
Sep 2007 | - | $18.93 M(-14.2%) |
Jun 2007 | - | $22.07 M(-11.4%) |
Mar 2007 | - | $24.91 M(+13.1%) |
Dec 2006 | $22.02 M(+430.7%) | $22.02 M(+2568.2%) |
Sep 2006 | - | $825.40 K(-11.4%) |
Jun 2006 | - | $932.10 K(+3.2%) |
Mar 2006 | - | $903.20 K(-78.2%) |
Dec 2005 | $4.15 M(+736.7%) | $4.15 M(+842.5%) |
Sep 2005 | - | $440.30 K(-6.8%) |
Jun 2005 | - | $472.20 K(-2.6%) |
Mar 2005 | - | $485.00 K(-2.2%) |
Dec 2004 | $496.00 K(-24.3%) | $496.00 K(-5.9%) |
Sep 2004 | - | $526.90 K(-7.6%) |
Jun 2004 | - | $570.20 K(-9.3%) |
Mar 2004 | - | $628.70 K(-4.1%) |
Dec 2003 | $655.40 K(-12.9%) | $655.40 K(-6.6%) |
Sep 2003 | - | $701.60 K(-4.4%) |
Jun 2003 | - | $733.90 K(-3.9%) |
Mar 2003 | - | $763.70 K(+1.4%) |
Dec 2002 | $752.90 K(-14.3%) | $752.90 K(-5.5%) |
Sep 2002 | - | $796.50 K(-3.2%) |
Jun 2002 | - | $822.60 K(-3.1%) |
Mar 2002 | - | $848.90 K(-3.4%) |
Dec 2001 | $878.90 K(-29.0%) | $878.90 K(+3.1%) |
Sep 2001 | - | $852.70 K(-12.0%) |
Jun 2001 | - | $969.20 K(-10.7%) |
Mar 2001 | - | $1.09 M(-12.4%) |
Dec 2000 | $1.24 M(+4.6%) | $1.24 M(-11.3%) |
Sep 2000 | - | $1.40 M(+10.9%) |
Jun 2000 | - | $1.26 M(+5.2%) |
Mar 2000 | - | $1.20 M(+1.0%) |
Dec 1999 | $1.18 M(-2.6%) | $1.18 M(-25.6%) |
Sep 1999 | - | $1.59 M(-7.9%) |
Jun 1999 | - | $1.73 M(+60.1%) |
Mar 1999 | - | $1.08 M |
Dec 1998 | $1.22 M(-83.4%) | - |
Dec 1997 | $7.34 M(+1.2%) | - |
Dec 1996 | $7.25 M | - |
FAQ
- What is Protalix BioTherapeutics annual working capital?
- What is the all time high annual working capital for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics annual working capital year-on-year change?
- What is Protalix BioTherapeutics quarterly working capital?
- What is the all time high quarterly working capital for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics quarterly working capital year-on-year change?
What is Protalix BioTherapeutics annual working capital?
The current annual working capital of PLX is $24.40 M
What is the all time high annual working capital for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high annual working capital is $74.65 M
What is Protalix BioTherapeutics annual working capital year-on-year change?
Over the past year, PLX annual working capital has changed by +$11.95 M (+95.98%)
What is Protalix BioTherapeutics quarterly working capital?
The current quarterly working capital of PLX is $23.63 M
What is the all time high quarterly working capital for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high quarterly working capital is $79.97 M
What is Protalix BioTherapeutics quarterly working capital year-on-year change?
Over the past year, PLX quarterly working capital has changed by -$5.63 M (-19.23%)